Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Neurogene to Participate in H.C. Wainwright 28 th Annual Global Investment Conference

businesswire.com
NGNE Neurogene is scheduled to participate in the H.C. Wainwright 28th Annual Global Investment Conference. This is a routine event for companies to present to investors and does not inherently indicate positive or negative performance.

Neurogene to Participate in H.C. Wainwright 28 th Annual Global Investment Conference NEW YORK--( BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the H.C. Wainwright 28 th Annual Global Investment Conference.

Format: Management will participate in a fireside chat and investor meetings

Date: Tuesday, September 15 at 1:00 p.m. ET

A live webcast of the fireside chat will be accessible from the Investor Relations section of Neurogene’s website under events, where a replay of the event will also be available for a limited time.

About Neurogene

Neurogene (NASDAQ: NGNE) is a clinical-stage biotechnology company focused on developing life-changing genetic medicines for people and their families impacted by devastating neurological diseases. The Company is using a biology-first approach paired with optimized delivery to develop purpose-built genetic medicines, including programs powered by its novel and proprietary EXACT™ transgene regulation technology. Neurogene is advancing its lead gene therapy program, NGN-401, as a potential best-in-class, one-time treatment for Rett syndrome. For more information, visit neurogene.com or follow on LinkedIn.